Business context and reporting period
This is On Assignment, Inc.’s Form 10-K for the fiscal year ended December 31, 2013; the filing does not identify the issuer as Everforth Inc. The company provides contract, contract-to-hire, and permanent staffing in technology, life sciences, and healthcare through Apex, Oxford, Life Sciences, and Physician. Annual results are presented against 2012 unless noted; the filing also provides unaudited quarterly figures.
Financial performance and position
- Revenue: $1.632 billion, up 43.4% from $1.138 billion. Management attributed most of the increase to Apex, acquired in May 2012; on a pro forma basis including acquisitions from the start of 2012, revenue increased 14.9%.
- Profit: Gross profit was $488.4 million versus $355.9 million; gross margin declined to 29.9% from 31.3%. Operating income was $124.0 million versus $81.2 million. Continuing-operations net income was $54.4 million versus $36.5 million; net income was $84.5 million versus $42.7 million, including a $30.8 million after-tax gain on discontinued-business sales. Diluted EPS was $1.00 from continuing operations and $1.55 in total, versus $0.76 and $0.89, respectively.
- Cash flow: Operating cash flow was $110.5 million, up from $40.7 million. Investing used $68.4 million, including $110.7 million for acquisitions and $16.5 million of capital expenditures, partly offset by $59.9 million from business sales. Financing used $32.4 million. Cash increased to $37.4 million. Operating cash flow less capital expenditures was approximately $94.0 million.
- Liquidity and debt: Working capital was $180.9 million and current assets exceeded current liabilities by that amount. Debt was $399.8 million at year-end, versus $426.6 million a year earlier; $77.8 million was available under the revolving facility. The company reported a 2.20:1 funded-debt-to-EBITDA ratio and compliance with covenants. The weighted-average stated debt rate at year-end was 3.0%.
- Segments: Apex revenue was $942.5 million (57.7% of total), Oxford $412.2 million, Life Sciences $171.5 million, and Physician $105.8 million. Gross margins declined year over year in each segment; consolidated margin pressure primarily reflected Apex’s lower-margin revenue mix.
Material changes versus the prior period
- Apex contributed a full year of revenue in 2013, versus about 7.5 months in 2012. Its pro forma revenue grew 19.1% year over year.
- Oxford revenue rose 13.3%; Life Sciences rose 5.4%; Physician rose 3.1%. Management cited growth in assignment volumes and, in some segments, bill rates or permanent-placement fees, while also describing pricing and mix pressures.
- The company acquired CyberCoders for approximately $98.6 million and Whitaker Medical for approximately $21.3 million in December 2013. Their contributions to reported 2013 revenue were limited to the post-acquisition period.
- The company sold Nurse Travel in February and Allied Healthcare in December 2013. The businesses are presented as discontinued operations. Their combined 2013 revenue was $44.6 million, and the after-tax gain on sale was $30.8 million.
- Debt was refinanced in May 2013. A $15.0 million write-off of old loan costs reduced reported pretax income. SG&A as a share of revenue improved to 21.0% from 22.6%.
Outlook, risks, and unusual items
- Management said it expected markets served to improve with the economy, planned continued investment in existing businesses and permanent-placement capabilities, and expected 2014 capital expenditures of approximately $19.7 million. The filing provides no specific company revenue or earnings guidance.
- Key risks include economic cyclicality and customer demand, assignment and client termination flexibility, competition and pricing, attracting and retaining qualified professionals, healthcare regulation and reimbursement changes, payroll and benefit costs, contractor classification, and workers’ compensation and malpractice claims.
- Additional risks include variable-rate debt and covenant limits, acquisition integration and earn-out exposure, information-system and cybersecurity disruptions, government-contract compliance, and potential impairment of goodwill or intangibles. Goodwill was $574.9 million; management reported no 2013 impairment, but noted valuation sensitivity to assumptions and market conditions.
- Potential future acquisition earn-outs were approximately $16.0 million through 2015. The company accrued approximately $2.1 million for a nurse-pay class-action settlement. It reported no significant off-balance-sheet arrangements beyond operating leases and standby letters of credit.
- Auditors issued an unqualified opinion on the financial statements and internal controls. Management and the auditor excluded the newly acquired CyberCoders and Whitaker from the 2013 internal-control assessment. The filing also describes a prior-year balance-sheet reclassification and immaterial retrospective quarterly EPS adjustments.
Important facts for investors to verify
- Separate underlying continuing-operations performance from the $30.8 million after-tax divestiture gain and the $15.0 million loan-cost write-off.
- Assess whether revenue growth and gross-margin trends are sustainable, particularly for Apex and the lower-margin or price-pressured segments.
- Review acquisition integration, purchase-price allocations, CyberCoders and Whitaker earn-out assumptions, and the contribution of the December acquisitions.
- Confirm debt repayment, variable-rate exposure, revolving availability, and ongoing covenant headroom; management estimated a 100-basis-point rate change would affect annual interest expense by approximately $3.7 million after hedges.
- Monitor workers’ compensation and malpractice reserves, the nurse settlement, divestiture indemnities, and goodwill and intangible-asset valuations.